vTv Therapeutics Inc. ( VTVT ) is a late clinical-stage biopharmaceutical company that focuses on the development of therapies for Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and other chronic conditions. Its flagship candidate is Cadisegliatin (TTP399), an oral glucokinase activator beingMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, A ...

Company Overview - vTv Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on developing therapies for Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and other chronic conditions [1]. Key Product - The flagship candidate of the company is Cadisegliatin (TTP399), which is an oral glucokinase activator [1].

The consensus price target for VTVT has increased to $53.50, indicating growing optimism.Recent upgrade to a Zacks Rank #2 (Buy) reflects increased confidence in the company's earnings potential.Strategic partnerships and advancements in clinical trials for TTP399 and HPP737 are key drivers of positive outlook.vTv Therapeutics Inc. (NASDAQ:VTVT) is a clinical-stage biopharmaceutical company that focuses on developing oral treatments for diabetes and other diseases. The company is advancing several promising ...

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Thursday, February 26, 2026Time: 11:20 AM ET ...

Core Insights - vTv Therapeutics has expanded its license agreement with Newsoara Biopharma, granting Newsoara global rights to develop and commercialize the PDE4 inhibitor HPP737, which is aimed at treating inflammation-mediated diseases [1][3] - The agreement includes an upfront payment of $20 million, potential future development milestones of approximately $50 million, sales milestones of up to $65 million, and tiered royalties based on net sales [2][3] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for chronic diseases, particularly type 1 diabetes [8] - The company's lead product, cadisegliatin, is currently in a Phase 3 trial and has received Breakthrough Therapy designation from the FDA [6][8] Product Details - HPP737 is a selective phosphodiesterase type 4 (PDE4) inhibitor that has shown therapeutic activity in animal models of inflammation and has been well tolerated in phase 1 studies [3][4] - The drug aims to address unmet needs in inflammation-mediated diseases and may avoid gastrointestinal side effects commonly associated with other PDE4 inhibitors [4] Strategic Collaboration - The collaboration with Newsoara is seen as a strategic priority for vTv, enhancing its balance sheet and providing a significant source of potential value creation for shareholders [2][3] - Newsoara plans to leverage its development and commercialization capabilities to advance HPP737 and bring it to patients worldwide [3][9]

Company Overview - vTv Therapeutics (VTVT) is a biopharmaceutical company valued at $156 million, focusing on the discovery and development of orally administered small molecule drug candidates to address unmet medical needs [1] - The company is developing azeliragon TTP488 for Alzheimer's disease, currently in Phase 3 clinical trials, along with candidates for Type 1 and Type 2 diabetes, cancers, psoriasis, and COPD [1] Stock Performance - VTVT has experienced a significant surge of 182% over the past year, reaching a two-year high [4] - The stock recently traded at $41.35, with a 50-day moving average of $30.06, and has gained 51.55% in the last month [5] - Since the Trend Seeker issued a new "Buy" signal on December 8, the stock has increased by 35.86% [2] Technical Indicators - vTv Therapeutics scored a new two-year high of $41.49 on December 31 [3] - The company has a Weighted Alpha of +225.52 and a Relative Strength Index (RSI) of 77.02, indicating strong momentum [5] - Barchart gives vTv Therapeutics a 100% "Buy" opinion, with Wall Street leaning towards a "Strong Buy" rating and price targets reaching up to $47 [4][5]

Core Viewpoint - vTv Therapeutics has been upgraded to a Zacks Rank 2 (Buy), indicating an upward trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade reflects an improvement in vTv Therapeutics' underlying business, suggesting that investors may respond positively by driving the stock price higher [4]. - For the fiscal year ending December 2025, vTv Therapeutics is expected to earn -$3.35 per share, with a 9.2% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6][8]. - The upgrade to Zacks Rank 2 places vTv Therapeutics in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Viewpoint - vTv Therapeutics Inc. has announced a Phase 2 clinical study for cadisegliatin, an oral adjunctive therapy to insulin for type 2 diabetes, in collaboration with M42's Insights Research Organization & Solutions [1][2] Group 1: Clinical Study Details - The Phase 2 study protocol has been submitted to the Department of Health Abu Dhabi and aims to evaluate the safety and efficacy of cadisegliatin over a 12-month period [1] - The trial will enroll approximately 300 patients with type 2 diabetes who are treated with insulin, randomized into three groups: two cadisegliatin dose groups (400 mg and 800 mg once daily) and a placebo control group [1] - The trial will take place in the UAE, Jordan, and Tunisia, with the first patient visit expected in Q1 2026 [1] Group 2: Company and Product Information - Cadisegliatin (TTP399) is a novel oral small molecule being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes and has received Breakthrough Therapy designation from the FDA [4][6] - vTv Therapeutics is focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with cadisegliatin leading its clinical pipeline [6] Group 3: Collaboration and Market Potential - The collaboration with M42 allows vTv to expand the geographic footprint for cadisegliatin, targeting populations with high prevalence of type 2 diabetes, particularly in the UAE [2][3] - IROS, as the funding partner for the study, aims to leverage its expertise in clinical research to potentially impact the lives of millions with type 2 diabetes [3][7]

Core Viewpoint - vTv Therapeutics (VTVT) has shown a significant price increase of 41.4% over the past four weeks, with a mean price target of $37 indicating a potential upside of 25.2% from the current price of $29.56 [1] Price Targets and Analyst Consensus - The average price target for VTVT ranges from a low of $35.00 to a high of $40.00, with a standard deviation of $2.65, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates an 18.4% increase, while the highest suggests a 35.3% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about VTVT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 9.2% over the past month, with no negative revisions reported [12] - VTVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can often mislead investors, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - vTv Therapeutics (VTVT) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for vTv Therapeutics suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - The upgrade of vTv Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, vTv Therapeutics is expected to earn -$3.35 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6.2% over the past three months [8].